Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Phase II Clinical Trial: Multi-dosing the BCG Vaccine for Fibromyalgia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03582085
• Other study ID #: 18114
• Status: Withdrawn
• Phase: Phase 2
• Start date: January 1, 2022
• Est. completion date: January 1, 2023

Study information

• Verified date: April 2022
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators are doing this research study to explore whether the bacillus Calmette-Guérin (BCG) vaccine can be an effective treatment for fibromyalgia. The researchers believe that the BCG vaccine can benefit people with fibromyalgia by increasing immune signaling molecules, called cytokines. The Faustman Immunobiology Laboratory has previously studied BCG in long term type 1 diabetics, and found that BCG vaccinations showed a short and small pancreas effect of restored insulin secretion.

Eligible volunteers will be vaccinated with BCG in repeat fashion over a period of three years or receive placebo treatment. The investigators hypothesize that these repeat injections of BCG will reduce symptom severity by increasing immune signaling cytokines.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 1, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of fibromyalgia

• HIV antibody negative

• Normal complete blood count (CBC), LFT, metabolic panel

• Meets the requirements for pain measured by the widespread pain index and symptom severity scale

• Negative pregnancy test within 7 days before initiation of study drug (Female only)

Exclusion Criteria:

• History of HIV or hepatitis

• History of tuberculosis, mycobacterium exposure, TB risk factors, positive interferon-gamma release assay (IGRA, also known as T-SPOT.TB test) or BCG vaccination

• Current treatment with glucocorticoids or disease likely to require steroid therapy

• Conditions or treatments associated with risk of infections such as patients with a previous history of severe burns, or treatment with immunosuppressive medications of any type

• Daily use of aspirin > 160 mg, or chronic, daily NSAIDs

• Current treatment with antibiotics

• History of keloid formation

• Severe pain due to other conditions

• Current treatment with any Type II diabetes medication (such as metformin, farxiga, etc.)

• Pregnant or not using acceptable birth control

• Living with someone who is immunosuppressed and/or at high risk for infectious diseases

Related Conditions & MeSH terms

• Fibromyalgia
• Myofascial Pain Syndromes

Intervention

Biological:
• Bacillus Calmette Guerin Vaccine
Experimental
• Saline Injection
Placebo

Locations

Country	Name	City	State
United States	Immunobiology Labs CNY 149	Charlestown	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in overall fibromyalgia symptoms since beginning the clinical trial, as measured by the Patient Global Impression of Change (PGIC)	The Patient Global Impression of Change (PGIC) is used to assess any change in their fibromyalgia since beginning the clinical trial. The PGIC asks patients to describe the change in activity limitations, symptoms, emotions, and overall quality of life on a scale from 0 to 7 since the start of the trial. A score of 0 is characterized by "no change (or condition has gotten worse)" and 7 is characterized by "a great deal better, and considerable improvement that has made the difference", thus, a higher score indicates overall improvement. The PGIC also asks patients to score the degree of change since beginning care at the clinic from 0 to 10. A score of 5 represents no change, while 0 represents "much better" and 10 represents "much worse", thus, a lower score on this question demonstrates a better outcome. These two scores are reviewed separately.	3 years
Primary	Intensity of specific symptoms pertaining to fibromyalgia, as measured by the Revised Fibromyalgia Impact Questionnaire (FIQ-R)	The Revised Fibromyalgia Impact Questionnaire (FIQ-R) measures how fibromyalgia affects quality of life. The FIQ-R asks patients to rate how difficult it is to perform a list of 9 common activities over the previous 7 days on an 11 point scale (ranging from "no difficulty" to "very difficult". The FIQ-R then asks patients to indicate how often their fibromyalgia impacts their quality of life over the last 7 days on an 11 point scale (ranging from "never" to "always"). Finally, the FIQ-R asks patients to assess the severity of their symptoms on an 11 point scale (ranging from no symptoms to extreme symptoms). These three sub-scales are summed to represent an overall FIQ-R score. A lower value for the FIQ-R represents a better outcome (less severe fibromyalgia).	3 years
Secondary	Intensity of Pain, as measured by the Short-Form McGill Pain Questionnaire (SF-MPQ)	The Short-Form McGill Pain Questionnaire (SF-MPQ) is used to assess fibromyalgia symptoms regarding pain. Patients are asked to rate 15 pain related sensations (throbbing, aching, stabbing, etc.) on a scale of 0 ("none") to 3 ("severe"). Patients are then asked to rate overall pain from 0 ("no pain") to 5 ("excruciating"). These scores are summed to give an overall value for pain, where a low score represents a better outcome (low pain).	3 years
Secondary	Severity of symptoms regarding anxiety and depression, as measured by the Hospital Anxiety and Depression Scale (HADS)	The Hospital Anxiety and Depression Scale (HADS) measures symptoms of anxiety and depression in fibromyalgia. Patients are instructed to rank how much they experience a list of 8 symptoms of anxiety and 8 symptoms of depression on a scale of 0 to 3. 0 represents less extreme symptoms and 3 represents very severe symptoms. These 16 questions are summed such that a low score represents a better outcome (less extreme symptoms of anxiety and depression).	3 years
Secondary	Difficulty with cognitive tasks, as measured by the Cognitive Function (CF) scale	The Cognitive Function (CF) scale measures how often patients struggle with a variety of cognitive tasks. The CF scale lists 25 cognitive tasks and asks patients to assess how often they struggle on a 5 point scale from "very often" to "never". These scores are summed, and a total high score represents better cognitive function and thus a better outcome.	3 years
Secondary	Intensity of fatigue, as measured by the Multidimensional Assessment of Fatigue (MAF) Scale	The Multidimensional Assessment of Fatigue (MAF) Scale asks patients 3 questions regarding how intensely they experience fatigue on a scale of 1 (little fatigue) to 10 (severe fatigue). These scores are summed, and a lower total score represents a better outcome.	3 years
Secondary	Severity and frequency of headaches, as measured by the Headache Questionnaire (HQ)	The Headache Questionnaire (HQ) asks a list of 10 questions regarding the severity and frequency of headaches. These scores are summed, and lower score indicates a better outcome (less frequent and severe headaches).	3 years
Secondary	Difficulty regarding sleep, as measured by the Questionnaire Regarding Sleep (QRS)	The Questionnaire Regarding Sleep (QRS) assesses the quality and quantity of sleep each night. Patients are asked 11 questions relating to how much they sleep (recorded in number of hours) and how often they experience poor sleep quality (on a scale of 0 to 4, where 0 represents not at all and 4 represents very often). These scores are reviewed separately. A high score for how much they sleep demonstrates a better outcome (more sleep) and a low score for how often they experience poor sleep quality demonstrates a better outcome (better sleep quality).	3 years

External Links

•   Faustman Lab Research Website